Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers-Reference-Cited by-同舟云学术

Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers

Published:2018-12-03 Issue:1 Volume:25 Page:89-94
ISSN:1078-8956
Container-title:Nature Medicine
language:en
Short-container-title:Nat Med

Author:

Scheper Wouter,Kelderman Sander,Fanchi Lorenzo F.,Linnemann Carsten,Bendle Gavin,de Rooij Marije A. J.,Hirt Christian,Mezzadra Riccardo,Slagter Maarten,Dijkstra Krijn,Kluin Roelof J. C.,Snaebjornsson Petur^ORCID,Milne Katy,Nelson Brad H.,Zijlmans Henry,Kenter Gemma,Voest Emile E.,Haanen John B. A. G.^ORCID,Schumacher Ton N.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

http://www.nature.com/articles/s41591-018-0266-5.pdf

Reference34 articles.

1. Ribas, A. & Wolchok, J. D. Cancer immunotherapy using checkpoint blockade. Science 359, 1350–1355 (2018).

2. Galon, J. et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313, 1960–1964 (2006).

3. Zhang, L. et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 348, 203–213 (2003).

4. Sharma, P. & Allison, J. P. The future of immune checkpoint therapy. Science 348, 56–61 (2015).

5. Tumeh, P. C. et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515, 568–571 (2014).

Cited by 437 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Driver mutation subtypes involve with differentiated immunophenotypes influencing pancreatic cancer outcomes;Cancer Letters;2024-09

2. MHC class I and II-deficient humanized mice are suitable tools to test the long-term antitumor efficacy of immune checkpoint inhibitors and T-cell engagers;Journal for ImmunoTherapy of Cancer;2024-09

3. Tumor-reactive T cell clonotype dynamics underlying clinical response to TIL therapy in melanoma;Immunity;2024-09

4. CD4 ⁺ tumor-infiltrating lymphocytes secreting T cell-engagers induce regression of autologous patient-derived non-small cell lung cancer xenografts;OncoImmunology;2024-08-27

5. Tumor battlefield within inflamed, excluded or desert immune phenotypes: the mechanisms and strategies;Experimental Hematology & Oncology;2024-08-06